Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of chidamide + ixazomib + cyclophosphamide + dexamethasone in relapsed/refractory multiple myeloma
ChiCTR2200066532Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Union Hospital
- Start
- Dec 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat, ixazomib, cyclophosphamide and dexamethasone in multiple myeloma (MM), sponsored by Fujian Medical University Union Hospital. Primary endpoint: Objective response rate. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
tucidinostatixazomibcyclophosphamidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2200066532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066532.